We provide a quick turnaround, offering actionable results to guide Rapid Precision Medicine™ and improve patient outcomes.
Rapid, robust phenotype-driven results are delivered to inform medical management
We expedite disease-specific molecular diagnoses in time to make a clinical difference.
We equip clinicians with insights on evidence-based intervention options.
Every minute matters when a child is struggling to survive. We identify or rule out the root causes of genetic disorders in record time.
See time to provisional positive report delivery below.
Ultra-rapid Whole Genome Sequencing | Rapid Whole Genome Sequencing Proband Only | Rapid Whole Genome Sequencing Duo | Rapid Whole Genome Sequencing Trio | Standard/DxO Whole Genome Sequencing Proband Only | Standard/DxO Whole Genome Sequencing Trio | Standard/DxO Whole Genome Sequencing Additional Family Member | |
---|---|---|---|---|---|---|---|
Test Type | urWGS | rWGSP | rWGSD | rWGST | WGSP | WGST |
WGS Additional Family Member |
Preliminary Positive Report TAT (days) |
≤ 3 calendar days |
≤ 5 business days |
≤ 5 business days |
≤ 5 business days | N/A | N/A | N/A |
Days to Final Report | ≤ 14 calendar days | ≤ 14 calendar days | ≤ 14 calendar days | ≤ 14 calendar days |
≤ 45 calendar days |
≤ 45 calendar days |
≤ 45 calendar days |
Samples Required From | Patient | Patient |
Patient One Family Member |
Patient Two Family Members |
Patient |
Patient two Family Members |
One Family Member |
For full test specifications go to Clinicians Toolbox
TEST | TAT | SNVs & INDELS | CNVs (1 kb) ANEUPLOIDY | MITOCHONDRIAL | SMA |
---|---|---|---|---|---|
RCIGM Ultra-rapid WGS | ≤ 3 calendar days* |
SMN1 & SMN2 Copy Number Analysis |
|||
RCIGM Rapid WGS | ≤ 5 business days* |
SMN1 & SMN2 Copy Number Analysis |
|||
Commercial Lab Rapid WGS | 1-2 weeks | Limited | |||
Chromosomal Microarray | 1-2 weeks | Limited | |||
Targeted Gene Panel | 4-6 weeks | Limited | mDNA panel | SMA panel |
*Time to provisional, positive report SNV – single nucleotide variant CNV – copy number variant Indel – small insertion/deletion
rWGS® is best considered for critically-ill infants and children in the inpatient setting for which a rapid genetic diagnosis could impact medical management and outcomes.
Indications for rWGS® testing include:
Benign and Likely Benign variants are not reported. In addition, RCIGM-CGC does not offer reporting on carrier status, pharmacogenetic markers, polygenic risk scores, or genome wide association studies (GWAS) risk variants.
Our Business Development team is here to answer your questions
© 2024 Rady Children's Institute for Genomic Medicine.